We also found that CBP-12-OVA inhibited B16-OVA tumor growth and enhanced antigen-specific CD8+ T cells responses, consistent with the conclusion that antigens targeting Clec9a in the presence of an adjuvant promoted tumor immunity 12 (Figure S7). Here, CLEC9A is linked to neoplasm.